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Abstract : In recent years, Endothelin-1 (ET1), Platelet Activating Factor (PAF) and
thromboxane
have
been
considered
responsible for the pathogenesis of acute
cyclosporine nephrotoxicity (ACN). The aim of
this study was to investigate the effects of the
PAF antagonist gingko glycosid (EGb 761) on
both renal histology and ET-1 and Nitric Oxide
(NO) levels in experimental ACN.
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This study was carried out on 30 albino
rabbits, divided into three groups. They were:
group A (n=10) the control, group B (n=10),
which was given intravenous cyclosporine
(15mg/kg/day) and group C (n=10), which
was
given
oral
gingko
glycosid
(2.5mg/kg/day) in addition to cyclosporine.
Plasma ET-1 and NO levels and renal histology
were investigated in all of the groups. Data
analysis was performed by Kruskall-Wallis
one-way Anova and Mann Whitney-U tests.

Plasma ET-1 levels in groups B and C were
higher than in the controls (p<0.0002,
p<0.0002, respectively). Plasma NO levels in
groups B and C were lower than in the
controls (p<0.0002, p<0.0047, respectively).
However, group C had high NO levels and low
ET-1 levels compared to group B (p<0.004,
p<0.0002, respectively). Renal histological
findings of ACN were observed in group B,
and to a lesser extent in group C.
Consequently, it was established that the PAF
antagonist Gingko glycosid Egb 761 partially
improved both the renal histology and plasma
ET-1 and NO levels in experimental ACN.
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Introduction

Materials and Methods

The immunosupressive agent cyclosporine improves
graft survival in renal transplantation (1). Cyclosporineinduced acute nephrotoxicity is reversible and is
characterized by a decrease in the glomerular filtration
rate secondary to vasoconstriction, occuring generally on
the afferent arteriole (2,3). The mechanism of this
vasoconstriction is not yet entirely clear but has been
linked more recently to the release of endothelin-1 (ET1), platelet activating factor (PAF) and thromboxane
(3,4).

The present study was performed using 30 albino
rabbits (weight 2250-3000g, age 13-15 months).
Animals were fed a laboratory diet ad libitum and tap
water.

The aim of the present study was to investigate the
effects of the PAF antagonist gingko glycosid (EGb 761)
on both renal histology and plasma ET-1 and nitric oxide
(NO) in rabbits with acute cyclosporine nephrotoxicity
(ACN).

Drugs, Reagent and Chemicals
Cyclosporine was obtained from Sandoz (Sandimmun,
50mg/mL amp., Basel, Switzerland). The PAF antagonist
Gingko glycosid (EGb 761) was obtained from Abdi
Ibrahim (Tebokan forte gutts, 9.6mg/mL/20gutts by Dr.
Willmar Schwabe License, Istanbul, Turkey). Aprotinin
was obtained from Bayer (Trasylol, 50mL, 500.000KIU,
Istanbul, Turkey). A radioimmunoassay kit (Code RPA
535) for endothelin-1 was purchased from Amersham
(Arlington Heights, Ill., USA). To determine nitric oxide
(NO), 35% sulphosalysilic acid, Griess reagent (1g/L
sulphanilamide, 25g/L phosphoric acid, 0.1g/L N-1
naphthylethylenediamine), 50µmol/L nicotinamide adenin
dinukleotid phosphate (NADPH), 5mmol/L flavin adenin
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dinucleotide, 10mg/L lactic dehydrogenase, 10mmol/L
sodium pyruvate and 200U/L nitrate reductase were
used. The nitrate reductase was purchased from
Boehringer Mannheim (Germany), while the others were
obtained from Sigma (USA).
Administration of drugs
The animals were divided into three groups. There
were 10 animals in each group. The first group (group A)
was selected as the control. Cyclosporine was given to the
second group (group B). Cyclosporine and Gingko
glycosid Egb 761 were given to the third group (group
C).
A catheter was introduced into the right jugular vein
and was extracted through a tunnel under the
interscapular area. 15 mg/kg/day of cyclosporine was
infused intravenously through this catheter for five days
in both group B and group C.
2.5 mg/kg body weight/day of the Gingko glycosid
Egb 761 was given orally together with food and water.
It was started 3 days before the cyclosporine and
continued throughout the experiment.
Procedures
Venous blood samples from all the rabbits were put
into silicone tubes, containing 7.5mM EDTA for the
plasma ET-1 and NO determinations. The samples were
taken after the administration of drugs in groups B and
C. Aprotinin (500KIU/mL blood) was added to the plasma
for measuring ET-1.
The rabbits were anesthetized intraperitoneally with
Ketamine (100mg/kg). Kidneys were isolated from the
surrounding tissues through a median abdominal incision
in both the control group and the experimental groups,
and were then harvested. Then, the animals were killed
with high dose sodium thiopental (2 g) given
intravenously. For histological evaluation, the harvested
kidneys were fixed in 10% formalin for at least 3 days. A
longitudinal piece was embedded in paraffin. Sections 3
µm thick were cut and stained with hematoxylin-eosin
(H&E), periodic acid schiff (PAS) and Masson’s tricrome.
Pathology and histology specialists, who had no
information about the study, examined the slides using a
light photomicroscope (Olympus BX-50, Japan).
Plasma endothelin-1 levels (pg/mL) were determined
using the method of Deray et al. (5). It is very difficult to
determine NO due to its radical nature and very short half
life (6). The plasma NO level is most often measured by
110

the determined stable end products of NO, nitrite and
nitrate (7). In the present study, plasma nitric oxide levels
(nmol/mL) were measured using the method of Moshage
et al (8). According to this method, total nitrite and
nitrate concentrations in plasma are determined using a
Griess assay. In addition, deproteinized plasma and
background controls for each sample are used in the
Griess assay to avoid obtaining artifactually high nitrite
and nitrate concentrations in plasma. Although, in some
published studies, samples were deproteinized, it is not
clear whether the controls were included (9,10).
Statistical analysis
The data were analyzed using Kruskall-Wallis one-way
Anova and Mann Whitney-U tests in the Statistical
Package for Social Sciences (SPSS). Statistical significance
was taken to be P<0.05. All data are expressed as mean
(X) ± standard deviation from the mean (SD).

Results
The plasma ET-1 (range:18-90pg/mL) and NO levels
(range:5-20nmol/mL) of all the rabbits are summarized
in Table 1.
Table 1.

Plasma ET-1 and NO levels (mean±SD) and ranges in
groups
ET-1(pg/mL)

NO(nmol/mL)

Group A

22±2.9 (18-27)

Group B

77±8.0 (68-90)

Group C

#
#,&

39±5.3 (30-47)

16.0±2.4 (12-20)
#

8.0±1.9 (5-11)

ψ,⊗

12.7±1.8 (10-16)

#

p<0.0002 when compared with group A;

&

p<0.0002 when compared with group B;

ψ

p<0.004 when compared with group A;

⊗

p<0.004 when compared with group B.

The plasma ET-1 and NO levels of the animals in
groups A, B and C were significantly different
(p<0.00001, p<0.00001, respectively). Compared to
those of the controls, ET-1 levels were high in group B
and group C. Although the ET-1 level of group C had
decreased compared to group B, its level was still higher
than that in the controls. NO levels were lower in group
B and group C than in the controls. The NO level of group
C was higher than that of group B, but its level was still
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low. Thus, Gingko glycosid partially improved the levels
of plasma ET-1 and NO in ACN.
Histological data
In the rabbits given cyclosporine, the tubules were
dilated, minimal interstitial edemas and a small number of
lymphocytes in the peritubular area were present with
isometric cytoplasmic vacuoles in some of the proximal
tubular epithelial cells (Figure 1A), prominently
thickening in the walls of arterioles associated with
muscle layers (Figure 1B) and obliteration with thrombi
in some arterioles (Figure 1C).
Figure 1C.

Thrombosis in the arterioles (arrow) ( H&Ex100).

arterioles was observed and there were less interstitial
edemas and vacuoles in the proximal tubular epithelial
cells (Figure 2).

Figure 1A.

Isometric cytoplasmic vacuoles in renal proximal tubular
cells (H&Ex400) in rabbits with acute cyclosporine
nephrotoxicity.

Figure 2.

The effects of Gingko glycosid Egb 761 on the renal
histology of rabbits with acute cyclosporine nephrotoxicity.
The reduction at vacuolization in the proximal tubular cells
are indicated (arrow) (H&Ex200).

Discussion

Figure 1B.

The prominent thickening in the arteriole wall associated
with muscle layer (arrow) (H&Ex200).

In the rabbits given gingko glycosid (EGb 761)
together with cyclosporine, no thrombosis in the

Cyclosporine directly damages vascular endothelial
cells in culture and in vivo (11, 12). The endothelial cell
damage leads to the release of the prostaglandings, NO
and ET-1. It has been found that plasma ET-1 levels are
high in animals given cyclosporine (13). ET-1 mediates
the acute renal vasoconstriction induced by cyclosporine.
In addition, pharmacologic blockade of the ET-1 receptor
has been found to be beneficial in treating ACN (14). It
has been reported that cyclosporine-induced nephropathy
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improves through chronic dietary supplementation of the
NO substrate L-arginine (15, 16). Therefore, this renal
disease is presented as an example of NO deficiency states
(17). In the present study, high ET-1 and low NO levels
were found in the plasma. These results confirm that
there is vascular endothelial damage in ACN.
Upon histologic examination of ACN, classical data
include epithelial cell vacuolization associated with
vascular changes consisting of endothelial cell swelling,
intimal thickening, hyalinosis and luminal occlusion (18).
Similar findings were obtained in the present study.
Endothelin-1 stimulates Platelet Activating Factor
(PAF) synthesis in endothelial cells (19). The kidney has
the greatest amount of PAF of all the organs (20).
However,
PAF is
synthetized
by
platelets,
polymorphonuclear neutrophils, monocytes, and
endothelial cells (21, 22). PAF has a biphasic effect on
afferent arterioles, dilating them that at low
concentrations while constricting them at higher
concentrations (23). It has been found that PAF is a direct
mediator of ACN (24).

the PAF receptor antagonist gingko glycoside EGb 761
was given orally to rabbits associated with cyclosporine,
plasma ET-1 levels decreased and NO levels increased. In
addition, there were fewer histologically abnormal
findings than in rabbits given only cyclosporine. Thus, it
may be suggested that the cyclosporine-induced
impairment of renal function and histology is minimized
by a PAF antagonist. These results are in accordance with
the findings of other studies (24, 26). Furthermore, PAF
antagonist improves post-transplant renal function in
patients receiving cadaveric kidney transplantation (27),
and shows a renal protective effect against warm renal
ischemia (28).
As a result, high plasma ET-1 and low plasma NO
associated with abnormal renal histology were found in
the ACN, and the PAF antagonist Gingko glycosid EGb
761 improved the renal histology of the ACN, decreased
ET-1 levels, and increased NO levels. Therefore, it may be
suggested that a PAF antagonist may be suitable for
clinical use in renal transplantation because of its
beneficial effects.

PAF receptor antagonist reduces cyclosporine
nephrotoxicity by improving whole kidney clearances and
glomerular morphology (25). In the present study, when
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